OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.
Moderna initiates BLA submission; GSK Earns EUA for mAb Treatment
Mass spectrometry and automation are growing in importance for protein characterization.
The COVID-19 pandemic has triggered additional considerations to supplier oversight.
June 08, 2021
FDA has granted Janssen breakthrough therapy designation for teclistamab, an investigational bispecific antibody under development for treating relapsed or refractory multiple myeloma.
June 07, 2021
FDA has granted accelerated approval to Biogen for Aduhelm (aducanumab), a new mAb treatment for Alzheimer’ disease.
The Biden administration supports a notable increase in funding for public health and research as a lead priority for the coming year.
The Module Type Package standard is now supported in Emerson’s DCS and PLCs.
June 04, 2021
Well-defined studies are crucial to effective process development.
The acquisition of Advanz Pharma by Nordic Capital has now completed, in a deal worth $846 million.
June 03, 2021
Hovione has re-joined iBET to increase its R&D programs in novel and high potential pharmaceutical technologies and to combine expertise for industrial innovation in new therapeutic fields.
Through the acquisition, Aceto can now offer its customers support throughout the drug development process and access to North American manufacturing for APIs and advanced intermediates.
The added capabilities include clinical-scale sachet and blister packaging for clinical trial pharmaceuticals and a relationship with a European Union Qualified Person for its CTS offerings.
June 02, 2021
As COVID-19 continues to spread, industry leaders are banding together to stop the disease in its tracks.
GoSilico’s software for digital twins of downstream biopharmaceutical processes will be integrated into Cytiva.
Currently, PNI offers a Genetic Medicine Toolkit, including its GenVoy LNP delivery platform and NanoAssemblr microfluidic-based nanoparticle manufacturing platform, for the development of genetic medicines.